Pictet Asset Management
TGTX icon

Pictet Asset Management’s TG Therapeutics TGTX Stock Holding History

Pictet Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.1M Buy
1,785,951
+38,578
+2% +$1.58M 0.09% 233
2026
Q1 		$58M Buy
1,747,373
+286,325
+20% +$8.53M 0.06% 286
2025
Q4 		$43.6M Sell
1,461,048
-148,503
-9% -$4.85M 0.04% 351
2025
Q3 		$58.1M Sell
1,609,551
-297,940
-16% -$9.81M 0.06% 295
2025
Q2 		$68.7M Sell
1,907,491
-489,693
-20% -$18.2M 0.07% 259
2025
Q1 		$94.5M Sell
2,397,184
-396,747
-14% -$13.3M 0.11% 210
2024
Q4 		$84.1M Sell
2,793,931
-788,652
-22% -$22.6M 0.09% 226
2024
Q3 		$83.8M Buy
3,582,583
+339,102
+10% +$7.41M 0.09% 224
2024
Q2 		$57.7M Sell
3,243,481
-83,733
-3% -$1.34M 0.07% 256
2024
Q1 		$50.6M Sell
3,327,214
-58,031
-2% -$924K 0.06% 310
2023
Q4 		$57.8M Buy
3,385,245
+2,564,842
+313% +$29.8M 0.06% 275
2023
Q3 		$6.86M Buy
+820,403
New +$11.4M 0.01% 704

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Pictet Asset Management's TGTX Position: Q2 2026 in Review

Pictet Asset Management increased its TG Therapeutics (TGTX) stake by 2.2% in Q2 2026, buying an estimated $1.58M and bringing the position to 1,785,951 shares worth $98.1M. The position accounts for 0.09% of the portfolio, ranked #233.

Pictet Asset Management first reported a position in TGTX in Q3 2023 and has held it in 12 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Pictet Asset Management held 1,785,951 shares of TG Therapeutics worth $98.1M as of Q2 2026.
  • Pictet Asset Management bought 38,578 TG Therapeutics shares in Q2 2026, an estimated $1.58M.
  • TG Therapeutics made up 0.09% of Pictet Asset Management's portfolio in Q2 2026, its #233 holding.
  • Pictet Asset Management first reported a position in TG Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.